The company is launching Rexulti (brexiprazole) for the treatment of adult patients with schizophrenia in Switzerland from 1 January 2019.
The launch is the first in a sequence that will see the treatment made available in other European countries during 2019 and 2020.
“We are delighted to be able to offer patients in Europe a new treatment of schizophrenia, which is a disease with big unmet medical needs. Introducing brexpiprazole in Switzerland is the first step in introducing brexpiprazole to other European countries and more countries globally,” says Jacob Tolstrup, Executive Vice President, Commercial Operations, Lundbeck.
In Switzerland brexpiprazole will be branded as Rexulti, while it will be branded as Rxulti in countries within the European Union. Currently brexpiprazole is approved and on the market in the United States, Australia, Canada, Saudi Arabia, and Japan.
Photo of Jacob Tolstrup: Lundbeck